Importance of HPV Genotyping for the Screening, Therapy and Management of Cervical Neoplasias.
Open accessAbstract
In the last decade, the detection of human papillomaviruses (HPV) has become increasingly important in cervical cancer screening and the treatment of cancer precursors. HPV screening is recommended for the further evaluation of abnormal Pap tests or during follow-up after treating precancerous lesions. Several randomised controlled studies have shown that screening for cervical cancer using HPV detection can be more effective than cytology alone. Genotyping of different high-risk HPV (hrHPV) types obtained from smear tests has not yet gained widespread acceptance in clinical practice. However, significant differences have been noted in the oncogenicity of hrHPV genotypes. HPV 16 is by far the most common and oncogenic genotype. Genotyping of hrHPV could be helpful for the risk stratification of HPV-positive women.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HPV genotyping is needed to distinguish transient HPV infections from permanent HPV infections.
“distinguish transient HPV infections from permanent HPV infections [26]”
From Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping (2022) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 18
- Poljak M, Kocjan BJ. Commercially available assays for multiplex detec- tion of alpha human papillomaviruses. Expert Rev Anti Infect Ther 2010; 8: 1139-1162
- Meijer CJ, Berkhof J, Castle PE et al. Guidelines for human papillo- mavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-520
- Naucler P, Ryd W, Tornberg S et al. Efficacy of HPV DNA testing with cy- tology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101: 88-99
- Bulkmans NW, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementa- tion trial. Lancet 2007; 370: 1764-1772
- Ronco G, Giorgi-Rossi P, Carozzi F et al. Efficacy of human papillo- mavirus testing for the detection of invasive cervical cancers and cer- vical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-257
- Dillner J, Rebolj M, Birembaut P et al. Long term predictive values of cy- tology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754
- de Sanjose S, Quint WG, Alemany L et al. Human papillomavirus geno- type attribution in invasive cervical cancer: a retrospective cross-sec- tional worldwide study. Lancet Oncol 2010; 11: 1048-1056
- Wheeler CM, Hunt WC, Joste NE et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101: 475-487
- Castle PE, Schiffman M, Wheeler CM et al. Human papillomavirus geno- types in cervical intraepithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev 2010; 19: 1675-1681
- Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079
- Schiffman M, Glass AG, Wentzensen N et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cer- vical neoplasia among 20,000 women in the Portland Kaiser cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20: 1398-1409
- Kjaer SK, Frederiksen K, Munk C et al. Long-term absolute risk of cervi- cal intraepithelial neoplasia grade 3 or worse following human papil- lomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102: 1478-1488 13
- Stoler MH, Wright jr. TC, Sharma A et al. High-risk human papillo- mavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011; 135: 468-475 14 Health Council of the Netherlands. Population screening for cervical cancer. Publication no. 2011/07. ISBN 978-90-5549-841-3. The Hague: 2011
- Kitchener HC, Almonte M, Gilham C et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009; 13: 1-150, iii-iv
- Anttila A, Kotaniemi-Talonen L, Leinonen M et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in pri- mary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010; 340: c1804 17
- Bulkmans NW, Rozendaal L, Snijders PJ et al. POBASCAM, a population- based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94-101
- Rijkaart DC, Berkhof J, Rozendaal L et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13: 78-88 19
- Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cer- vical cancer in rural India. N Engl J Med 2009; 360: 1385-1394 Deutschsprachige Zusatzinformationen online abrufbar unter: www.thieme-connect.de/ejournals/toc/gebfra.
Cited by
Sorted by citations
Kim, M., Kim, J., Park, N. J.-Y., & Park, J. Y. (2022) · PLOS ONE · doi:10.1371/journal.pone.0267836 · Cited by 5 · see citing works
“HPV genotyping is also needed to triage patients for cervical cancer screening [25], distinguish transient HPV infections from permanent HPV infections [26], and establish the impact of HPV vaccination programs [27, 28].”
Background
- Authors
- Jentschke, M., Soergel, P., & Hillemanns, P.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Jentschke, M.
- Venue
- Geburtshilfe und Frauenheilkunde
- Publisher
- Georg Thieme Verlag KG
- Published
- 2012-06
- Volume
- 72
- Issue
- 06
- Pages
- 507-512
- ISSN
- 0016-5751 (ISSN-L)
- 1438-8804
- PMC
- PMC4215574
- OpenAlex
- W2067056739
- Cited by
- 35
- References
- 0
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 1 · 2023: 2 · 2022: 8 · 2021: 1 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 6
- FWCI
- 1.92
- Type
- journal article
- Language
- de
- Open access
- bronze
- doi.org
- Locations
- Geburtshilfe und Frauenheilkunde (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Keywords
- HPV genotyping, human papillomavirus, cervical cancer screening, cervical neoplasia, high-risk HPV genotypes, HPV16, oncogenicity, risk stratification, Pap smear, precancerous lesions, HPV-based screening
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
